Arango, Natalia Yuca, Erkan Zhao, Ming Evans, Kurt Scott, Stephen Kim, Charissa Gonzalez-Angulo, Ana Janku, Filip Ueno, Naoto Tripathy, Debu Akcakanat, Argun Naing, Aung Meric-Bernstam, Funda Additional file 1: of Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer PIK3CA, PTEN, TP53 and Ras/Raf status of cell lines in panel. A panel of breast cancer cell lines was tested with selinexor, and cell growth was measured after 72 hours of treatment using the SRB assay. IC50 was then calculated using isobologram curves. The mutation statuses for PIK3CA, PTEN, TP53, and Ras/Raf status are reported. (DOCX 23 kb) Breast cancer;Selinexor;XPO1;PDX;TNBC 2017-08-15
    https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Selinexor_KPT-330_demonstrates_anti-tumor_efficacy_in_preclinical_models_of_triple-negative_breast_cancer/5314303
10.6084/m9.figshare.c.3854311_D1.v1